Genmab Announces Change in Management

Summary:  Dr. Claus Møller steps down from his position as Chief Operating      
Officer of Genmab.                                                              

Copenhagen, Denmark; September 3, 2008 - Genmab A/S (OMX: GEN) announced today  
that Claus Møller, M.D., Ph.D. has informed the Board of Directors of his       
intention to step down from his position as Executive Vice President, Chief     
Operating Officer of Genmab.  Dr. Møller's decision reflects his desire to      
concentrate on his role as Chairman of the board of IPC-International, Plc and  
to spend more time with his family having achieved his many career goals within 
Genmab.                                                                         

Dr. Møller will remain available to Genmab as Development Advisor during a      
transitional period for the remainder of 2008. The Chief Operating Officer      
position at Genmab will be discontinued and Dr. Møller's responsibilities will  
be folded into the research and development department which has already been   
consolidated under the direction of Prof. Jan G. J. van de Winkel, Ph.D.,       
President, Research and Development and Chief Scientific Officer, in conjunction
with an earlier expansion of the company's senior management team which now     
includes eight members.                                                         

“Claus was one of Genmab's founders ten years ago and has been an essential part
of building Genmab into a world leading biotechnology company. He has made      
significant contributions across a range of activities including the development
of ofatumumab. We wish to offer our sincere thanks to Claus for his many years  
of service with the company and wish him the best in his future endeavors,” said
Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.                     

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using cutting-edge  
antibody technology, Genmab's world class discovery, development and            
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders.  As Genmab advances towards a commercial future, we remain committed 
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options.  For more information on Genmab's products and           
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. For a     
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com.  Genmab does   
not undertake any obligation to update or revise forward looking statements in  
this press release nor to confirm such statements in relation to actual results,
unless required by law.                                                         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release No. 41/2008                                              

###